Jun 2026 (Q2 FY26) — Jul 29, 2026
PennyMac Financial Q2 FY26 — Technology-Driven Cost Reductions and Recapture Rate Growth Amidst Rate Headwinds
Read the full callPennyMac Financial earnings: last reported Wed, 29 Jul 2026, for the quarter ended Jun 2026.
Reported
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 19.5 | +331.7% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | Operating profit / revenue | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Net profit | 21.7 | −84.1% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
1Y: $119.7 on 14 Oct 2025 → $61.19. High $159.46 (16 Jan 2026), low $57.75 (14 Oct 2026).
Overview
Call summaries
PennyMac Financial Q2 FY26 — Technology-Driven Cost Reductions and Recapture Rate Growth Amidst Rate Headwinds
Read the full callEvery analysed call
Financials
Net profit, year on year: −84% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 3 | 4 | 5 | 5 | 5 | 6 | 6 | 19 |
| Profit before tax | 94 | 129 | 104 | 76 | 236 | 134 | 105 | 32 |
| Tax rate | 26.1% | 19.2% | 26.8% | −78.5% | 23.2% | 20.5% | 21.4% | 31.1% |
| Net profit | 69 | 104 | 76 | 136 | 182 | 107 | 82 | 22 |
| EPS ($ per share) | 1.36 | — | 1.48 | 2.64 | 3.51 | — | 1.58 | 0.42 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | — | — | — | — | — | 0 | 0 | 0 |
| Reserves | 343 | 726 | 2,342 | 3,293 | 3,471 | 3,514 | 3,774 | 4,212 |
| Total liabilities | 5,825 | 8,143 | 28,208 | 15,358 | 13,352 | 15,306 | 22,257 | 25,080 |
| Fixed assets | 33 | 30 | — | 32 | 28 | 19 | 13 | 18 |
| Investments | 118 | 75 | 15 | 7 | 12 | 10 | 421 | 410 |
| Total assets | 7,479 | 10,204 | 31,598 | 18,777 | 16,823 | 18,845 | 26,087 | 29,389 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 572 | -2,245 | -6,199 | 2,563 | 6,033 | -1,582 | -4,533 | -1,652 |
| Cash from investing | -323 | 149 | 783 | -304 | -722 | -273 | -1,888 | 552 |
| Cash from financing | -132 | 2,129 | 5,760 | -2,451 | -4,323 | 1,465 | 5,721 | 1,163 |
| Net cash flow | 118 | 33 | 344 | -193 | 988 | -390 | -700 | 63 |
| Capital expenditure | -13 | -6 | -11 | -8 | -7 | -1 | -2 | -12 |
| Free cash flow | 559 | -2,251 | -6,210 | 2,555 | 6,026 | -1,584 | -4,535 | -1,664 |
139 filings between Oct 22, 2025 and Jul 31, 2026.
Purchases
$200.6K
1 purchase by 1 insider
Sales
$34.61M
57 sales by 6 insiders
82% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Also filed: 4 other filings, 2 gifts, 1 disposition to issuer.
| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| SPECTOR DAVID | — | $16.83M | May 12, 2026 |
| Perotti Daniel Stanley | — | $6.77M | May 15, 2026 |
| Jones Doug | — | $6.19M | Nov 25, 2025 |
| MCCALLION ANNE | — | $3.65M | Oct 24, 2025 |
| Hendry Gregory L | — | $894.3K | Jul 1, 2026 |
| STARK DEREK | — | $267.6K | Mar 3, 2026 |
| Kinsella Patrick | $200.6K | — | Feb 12, 2026 |
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jul 31, 2026 | NANJI FARHAD Director | Award | 379 | $31.1K |
| Jul 31, 2026 | SPECTOR DAVID Chairman & CEO | Other | 25,000 | $0 |
| Jul 31, 2026 | Chandra Sunil Director | Award | 377 | $31.0K |
| Jul 1, 2026 | Hendry Gregory L MD, Chief Accounting Officer | Sale 10b5-1 plan | 2,177 | $189.2K |
| Jul 1, 2026 | Hendry Gregory L MD, Chief Accounting Officer | Option exercise 10b5-1 plan | 2,177 | $53.1K |
| Jun 22, 2026 | Hendry Gregory L MD, Chief Accounting Officer | Sale 10b5-1 plan | 2,943 | $240.5K |
| Jun 22, 2026 | Hendry Gregory L MD, Chief Accounting Officer | Option exercise 10b5-1 plan | 2,943 | $53.1K |
| May 15, 2026 | Perotti Daniel Stanley Chief Financial Officer | Sale 10b5-1 plan | 2,925 | $255.9K |
| May 12, 2026 | SPECTOR DAVID Chairman & CEO | Sale 10b5-1 plan | 4,084 | $362.3K |
| May 12, 2026 | SPECTOR DAVID Chairman & CEO | Sale 10b5-1 plan | 2,772 | $240.8K |
| May 12, 2026 | SPECTOR DAVID Chairman & CEO | Sale 10b5-1 plan | 3,144 | $276.7K |
| May 8, 2026 | SPECTOR DAVID Chairman & CEO | Other | 25,000 | $0 |
| May 7, 2026 | NANJI FARHAD Director | Award | 338 | $31.4K |
| May 7, 2026 | MAZZELLA JOSEPH F Director | Award | 359 | $33.4K |
| May 7, 2026 | Chandra Sunil Director | Award | 336 | $31.3K |
| Apr 14, 2026 | SPECTOR DAVID Chairman & CEO | Sale 10b5-1 plan | 417 | $39.0K |
| Apr 14, 2026 | SPECTOR DAVID Chairman & CEO | Sale 10b5-1 plan | 9,583 | $889.3K |
| Mar 6, 2026 | SPECTOR DAVID Chairman & CEO | Sale 10b5-1 plan | 729 | $62.2K |
| Mar 6, 2026 | SPECTOR DAVID Chairman & CEO | Sale 10b5-1 plan | 10,210 | $882.3K |
| Mar 6, 2026 | SPECTOR DAVID Chairman & CEO | Sale 10b5-1 plan | 1,020 | $88.7K |
| Mar 6, 2026 | SPECTOR DAVID Chairman & CEO | Sale 10b5-1 plan | 917 | $78.2K |
| Mar 6, 2026 | SPECTOR DAVID Chairman & CEO | Sale 10b5-1 plan | 1,309 | $113.8K |
| Mar 6, 2026 | SPECTOR DAVID Chairman & CEO | Sale 10b5-1 plan | 8,251 | $713.1K |
| Mar 3, 2026 | STARK DEREK Chief Legal Officer | Sale 10b5-1 plan | 1,066 | $93.4K |
| Feb 28, 2026 | ELBAUM MARK Chief Capital Markets Officer | Tax withheld | 71 | $6.5K |
| Feb 28, 2026 | Tidmore Abbie Chief Revenue Officer | Tax withheld | 300 | $27.6K |
| Feb 28, 2026 | Follette James Chief Digital Officer | Tax withheld | 599 | $55.1K |
| Feb 28, 2026 | Jones Doug Director, President & CMBO | Tax withheld | 1,704 | $156.6K |
| Feb 28, 2026 | Perotti Daniel Stanley Chief Financial Officer | Tax withheld | 849 | $78.0K |
| Feb 28, 2026 | STARK DEREK Chief Legal Officer | Tax withheld 10b5-1 plan | 467 | $42.9K |
| Feb 28, 2026 | Hendry Gregory L MD, Chief Accounting Officer | Tax withheld | 32 | $2.9K |
| Feb 28, 2026 | SPECTOR DAVID Chairman & CEO | Tax withheld | 3,097 | $284.7K |
| Feb 25, 2026 | STARK DEREK Chief Legal Officer | Sale 10b5-1 plan | 1,903 | $174.1K |
| Feb 24, 2026 | Tidmore Abbie Chief Revenue Officer | Tax withheld | 204 | $18.4K |
| Feb 24, 2026 | Follette James Chief Digital Officer | Tax withheld | 554 | $50.0K |
| Feb 24, 2026 | SPECTOR DAVID Chairman & CEO | Tax withheld | 3,106 | $280.6K |
| Feb 24, 2026 | STARK DEREK Chief Legal Officer | Tax withheld 10b5-1 plan | 345 | $31.2K |
| Feb 24, 2026 | Perotti Daniel Stanley Chief Financial Officer | Tax withheld | 616 | $55.6K |
| Feb 24, 2026 | Jones Doug Director, President & CMBO | Tax withheld | 1,597 | $144.3K |
| Feb 24, 2026 | Hendry Gregory L MD, Chief Accounting Officer | Tax withheld | 45 | $4.1K |
| Feb 20, 2026 | STARK DEREK Chief Legal Officer | Tax withheld | 780 | $73.6K |
| Feb 20, 2026 | STARK DEREK Chief Legal Officer | Option exercise | 2,130 | $0 |
| Feb 20, 2026 | Hendry Gregory L MD, Chief Accounting Officer | Tax withheld | 126 | $11.9K |
| Feb 20, 2026 | Hendry Gregory L MD, Chief Accounting Officer | Option exercise | 304 | $0 |
| Feb 20, 2026 | Perotti Daniel Stanley Chief Financial Officer | Tax withheld | 1,366 | $128.9K |
| Feb 20, 2026 | Perotti Daniel Stanley Chief Financial Officer | Option exercise | 3,805 | $0 |
| Feb 20, 2026 | SPECTOR DAVID Chairman & CEO | Tax withheld | 7,391 | $697.2K |
| Feb 20, 2026 | SPECTOR DAVID Chairman & CEO | Option exercise | 13,699 | $0 |
| Feb 20, 2026 | Tidmore Abbie Chief Revenue Officer | Tax withheld | 565 | $53.3K |
| Feb 20, 2026 | Tidmore Abbie Chief Revenue Officer | Option exercise | 2,054 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Free account. Everything above stays public.
Write why you follow PennyMac Financial Services, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading